Jefferies Maintains Verastem Inc to Hold with Price Target $1.50

Brokerage firm Jefferies Maintains its rating on Verastem Inc(NASDAQ:VSTM). In a research note issued to the investors, the brokerage major Lowers the price-target to $1.50 per share. The shares have been rated Hold. The rating by Jefferies was issued on Aug 9, 2016.

Verastem Inc (VSTM) shares turned negative on Wednesdays trading session with the shares closing down -0.02 points or -1.46% at a volume of 1,13,029. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.39. The peak price level was also seen at $1.39 while the days lowest was $1.32. Finally the shares closed at $1.35. The 52-week high of the shares is $7.73 while the 52-week low is $1.05. According to the latest information available, the market cap of the company is $50 M.

Verastem Inc(VSTM) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.23. Analysts had estimated an EPS of $-0.29.

Several Insider Transactions has been reported to the SEC. On Jun 30, 2015, Monica Singh (General Counsel) purchased 1,000 shares at $6.95 per share price.Also, On Jun 30, 2015, John B Green (CFO) purchased 500 shares at $7.12 per share price.On Jun 30, 2015, Robert Forrester (CEO) purchased 2,000 shares at $7.11 per share price, according to the Form-4 filing with the securities and exchange commission.

Verastem Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The Company has technology to create a stable population of cancer stem cells that it uses to screen for and identify small molecule compounds that target cancer stem cells. The Company’s solution includes the discovery and development of oncology therapeutics targeting cancer stem cells (CSCs). The Company is engaged in running clinical trials in cancers where CSCs were implicated in disease progression including mesothelioma ovarian non-small cell lung and other cancers such as breast cancer. The Company’s candidates include its FAK inhibitors VS-6063 and VS-4718 and VS-5584 its dual mTORC1/2 and PI3K inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *